Table 1.
Patient clinical characteristics of rheumatoid arthritis patients used in this study
| MC RA ACPA+ |
MC RA ACPA− |
FC RA ACPA+ |
FC RA ACPA− |
|
|---|---|---|---|---|
| n = 8 | n = 7 | n = 27 | n = 20 | |
| Age in years, average (range) | 64 (48–75) | 67 (54–79) | 55 (17–81) | 51 (21–86) |
| Females, n (%) | 4 (50) | 4 (57) | 16 (59) | 12 (60) |
| RF positive, n (%) | 8 (100) | 2 (29) | 19(79) | 5(21) |
| Elevated CRP, n (%) | 5 (50)a | 3 (25) | 62(24) | 38(15) |
| SJC, mean (range)b | 9 (3–20) | 14 (4–29) | 5 (0–20) | 3 (0–16) |
| TJC, mean (range)b | 11 (2–20) | 17 (1–34) | 3 (0–16) | 3 (0–18) |
| DMARD usage, n (%)c | 0 (0) | 0(0) | 6 (31%) | 4 (36%) |
| Disease duration (in days), average (range)d | 132 (13–600) | 42 (21–60) | 108 (5–542) | 132 (3–610) |
aNo CRP was recorded for one male and one female (male ESR = 34, female ESR = 126)
bFor 3 ACPA+ and 2 ACPA−, no SJC/TJC was recorded in the FC dataset
cFor 17 RA patients, no DMARD usage was recorded in the FC dataset, frequency of DMARD calculation based on n = 19 in ACPA+ and n = 11 in ACPA−. DMARD usage included hydroxychloroquine, sulfasalazine and methotrexate
dFor 1 ACPA+ and 1 ACPA−, no disease duration was recorded in the FC dataset
MC mass cytometry, FC flow cytometry, ACPA anti-citrullinated protein antibodies, RF rheumatoid factor, CRP C-reactive protein, SJC swollen joint count, TJC tender joint count, DMARD disease-modifying anti-rheumatic drugs